KPV

What it is

KPV is the smallest peptide worth talking about in this whole encyclopedia: three amino acids: Lysine, Proline, Valine — 342.43 g/mol (corrected 2026-06-21, PubChem CID 125672). It’s the C-terminal tripeptide (residues 11–13) of α-melanocyte-stimulating hormone (α-MSH), the hormone that, in its full form, drives skin pigmentation and a stack of melanocortin-receptor effects. (Naming trivia: it’s abbreviated “K”-P-V because the obvious “L” for Lysine was already taken by Leucine when the amino-acid shorthand was set in the 1960s.)

Here’s the engineering story that makes KPV interesting: researchers found that this little tail fragment carries α-MSH’s anti-inflammatory activity without activating the melanocortin receptors. That means no pigmentation, no flushing, no nausea, no sexual stimulation — none of the side-effect profile that comes with the other α-MSH-family peptides like Melanotan or PT-141. You isolate the calm-the-inflammation effect and leave the hormone behavior behind.

Its tiny size buys a second rare property: KPV actually works orally. Most peptides get shredded in the gut. KPV survives and gets ferried across the intestinal lining by a dedicated di/tripeptide transporter called PepT1 — which, as you’ll see, is exactly the right door to walk through when the target is gut inflammation.

The discovery story: Hiltz and Lipton at University of Texas Southwestern asked which part of α-MSH actually carried the anti-inflammatory activity. They isolated the C-terminal tripeptide (residues 11–13, KPV) and tested it. In their 1989 FASEB Journal paper (Hiltz ME, Lipton JM. FASEB J. 1989;3:2282–2284), KPV alone reduced inflammation in animal models as potently as a high-dose corticosteroid — a landmark result, because it proved you could carve out α-MSH’s anti-inflammatory effect and leave its hormone behavior behind. A 1990 follow-up showed KPV also blocked carrageenan-induced edema. Those two papers anchor the entire 36-year preclinical story.

Where you get it: KPV is not a standalone Alyve SKU. It’s the “K” in KLOW — Alyve’s BPC-157 + TB-500 + KPV + GHK-Cu blend. Most people asking “where do I buy KPV?” already have access through KLOW.

How it works

The core insight: KPV works inside the cell, not at the surface. Most anti-inflammatories try to intercept an inflammation signal before it reaches the cell. KPV gets transported into the cell and switches off inflammation from within.

• PepT1 transport. KPV enters cells via the PepT1 transporter, a di/tripeptide carrier normally found in the small intestine. The elegant part: PepT1 gets upregulated in the colon during inflammation — particularly in IBD. So KPV’s delivery door opens wider exactly when the gut is more inflamed, which means the more inflamed the tissue, the more efficiently KPV reaches the cells that need it. Cells that lack PepT1 show no KPV effect at all — proof the transporter is the route.
• NF-κB suppression: the specific molecular step. Once inside, KPV blocks the nuclear-import step of NF-κB activation, not the upstream signaling cascade. NF-κB’s active form is the p65 subunit, which needs the transport protein importin α-3 to cross into the nucleus and switch on inflammatory genes. KPV competitively binds the importin-α-3 binding site for p65 (specifically the armadillo-3 domain that recognizes p65’s nuclear localization signal), getting there first and preventing p65 from being escorted in. The alarm tries to fire and gets shut off at the nuclear door. Verified via Kannengiesser et al. 2012 Br J Pharmacol (PMID 22837805, PMC3403564) in human bronchial epithelial cells — the same paper anchors KPV’s gut-lung-axis use case. Downstream, the inflammatory cytokines drop: TNF-α, IL-1β, IL-6, IL-8, IL-12, IFN-γ.

It does this independently of melanocortin receptors: and that’s proven, not assumed. KPV’s anti-inflammatory and anti-leukocyte-migratory effects are retained in mice with a nonfunctional MC1R, KPV doesn’t raise intracellular cAMP the way other melanocortin peptides do, and it doesn’t compete with α-MSH for receptor binding (Getting et al.). So the receptor route everyone assumed it would use turns out not to be the main mechanism — KPV interferes with IL-1β-driven inflammatory signaling directly inside the cell.

A note on a real source disagreement: some educators in the field describe KPV as “acting through melanocortin receptors MCR1/MCR3.” The better-supported primary literature (the MC1R-null mouse data + the PepT1/NF-κB work) says the primary anti-inflammatory mechanism is receptor-independent. Any minor leftover melanocortin activity inherited from α-MSH isn’t the driver. We lead with the receptor-independent story because that’s where the evidence is.

Resolution pharmacology, not symptom suppression — how KPV differs from NSAIDs and corticosteroids. This is the pharmacological-class distinction most worth understanding, because almost every reader has tried one or both of the conventional alternatives. The three classes do fundamentally different things: [established immunology + resolution-medicine literature]

• NSAIDs (ibuprofen, naproxen, aspirin, etc.) block the COX enzymes that convert arachidonic acid into pro-inflammatory prostaglandins. Symptom output goes down because the production of certain inflammatory mediators is reduced. But COX-1 also produces the prostaglandins that protect the gastric lining and maintain renal blood flow, which is why chronic NSAID use carries documented gastrointestinal-bleeding, cardiovascular, and chronic-kidney-disease risk. The molecular debris of inflammation — damaged cells, oxidized lipids, persistent low-grade cytokine signaling — is still there. You’ve turned off some of the alarm without putting out the fire.
• Corticosteroids (prednisone, dexamethasone, cortisone) bind glucocorticoid receptors and suppress virtually all inflammatory gene transcription at once. Profoundly effective at reducing inflammation; profoundly suppressive of the immune system globally, with the documented metabolic (insulin resistance, steroid-induced diabetes), bone (osteopenia/osteoporosis), infection-risk, and HPA-axis-suppression tail. They’re appropriate emergency interventions; they’re catastrophic as long-term solutions.
• KPV does neither. It doesn’t block upstream COX signals and it doesn’t globally suppress the immune system. It surgically prevents NF-κB nuclear translocation (the specific molecular step covered above) while simultaneously upregulating IL-10 (the master anti-inflammatory cytokine) and shifting macrophages from the M1 pro-inflammatory phenotype toward the M2 pro-resolution phenotype. Net effect: instead of just shutting up the inflammatory signal, the system actively transitions to the clean-up + tissue-repair phase. The molecular debris gets cleared. The damaged tissue gets remodeled. The balance gets restored.

The conceptual frame in the broader immunology literature for what KPV does is “resolution pharmacology” — a class of interventions that act on the resolution phase of inflammation rather than the inflammatory phase. This is the same lane as the specialized pro-resolving mediators (SPMs) field (resolvins, protectins, maresins). Where NSAIDs and corticosteroids are anti-inflammatories, KPV is more accurately a pro-resolution mediator. The distinction matters because chronic unresolved inflammation — not acute inflammation — is what drives the long-tail damage in cardiovascular disease, neurodegeneration, metabolic syndrome, and many autoimmune presentations. Resolution is the goal; suppression is a short-term proxy that often makes the underlying problem worse over time.

Secondary mechanisms (consistent across the educator sources, mostly still awaiting primary-literature pinning):

• Tight-junction restoration → less “leaky gut.” KPV appears to help rebuild epithelial tight-junction proteins, reducing gut permeability — the concrete mechanism behind its leaky-gut and food-sensitivity use cases, not just “supports gut health.”
• Mast-cell + eosinophil modulation → the histamine-intolerance / MCAS / allergic-skin angle.
• TLR4 downregulation → dampens innate-immune overactivation to bacterial LPS (the leaky-gut → LPS → systemic-inflammation circuit).
• Mild antimicrobial activity vs S. aureus (incl. MRSA) and Candida — supplementary, not KPV’s main job.
• Bronchial NF-κB inhibition in human airway epithelial cells → a gut-lung-axis use case.

The unifying frame — and the right one for OHM’s voice — is modulation, not suppression. Unlike steroids, which blunt the whole immune system, KPV calms the over-firing inflammatory pathway while leaving normal defense intact. It guides the body’s own system back toward balance rather than overriding it.

What the research shows

Animal / preclinical: KPV’s home turf, and first-class evidence here.

• Dalmasso et al. 2008, Gastroenterology (PMID 18061177): the foundational paper. KPV is taken up into colonic cells via PepT1; oral KPV reduced both DSS- and TNBS-induced colitis in mice, cutting pro-inflammatory cytokine expression and disease severity. Cells lacking PepT1 showed no effect, nailing the transport mechanism. This single paper anchors both the oral-viability story and the PepT1/NF-κB mechanism. ✅ verified.
• Colitis-associated-cancer model, Cell Mol Gastroenterol Hepatol 2016 — PepT1-mediated KPV was anti-inflammatory and protective in a murine colitis-associated-cancer model. ✅ paper confirmed.
• Getting et al.: MC1R-null / crystal-induced peritonitis — the receptor-independence anchor: KPV’s effect survives a nonfunctional MC1R and is cAMP-independent.
• Retinal-microglia autophagy (AMPK/mTOR), 2023 — mechanistic basis for uveitis / dry-eye applications.
• Immobilized α-MSH 10–13 (GKPV) blocks TNF-α-stimulated NF-κB — supports the core NF-κB mechanism.

In-vitro / mechanism review. A 2023 review in Cells on melanocortin peptides reported that NF-κB-driven inflammation suppression improved metabolic syndrome independent of body weight — the basis for the honest “KPV is a context-setter, not a fat-loss drug” framing below.

• Lee et al. 2026, Cytotechnology Vol. 78(3):98 (PMID 42064835): KPV (100 µg/mL) significantly reduced oleic-acid-induced lipid accumulation and suppressed fatty acid synthase (FAS) expression in HepG2 hepatocytes without inducing cytotoxicity. Mechanism: KPV reduces reactive oxygen species (ROS) generation, which prevents ERK activation, which in turn blocks AKT/mTORC1 phosphorylation and normalizes PPARγ regulation — downstream, FAS expression falls and de novo lipogenesis is attenuated. The conclusion: KPV acts as an antioxidant regulator of lipogenic signaling and may hold potential as a therapeutic candidate for hepatocellular steatosis. Important caveats: HepG2 cells are a hepatocellular carcinoma cell line (not primary hepatocytes or tissue); single dose tested; no in-vivo arm. In-vitro hepatoprotection ≠ clinical NAFLD treatment. This is a meaningful new mechanism domain — KPV’s ROS/PPARγ axis in liver tissue is a distinct pathway from its NF-κB/importin-α3 gut-inflammation story — but it awaits in-vivo confirmation before clinical claims can be made.

Human evidence: the honest gap. There are zero completed human clinical trials of KPV in any indication, despite a 20+ year preclinical runway. Human pharmacokinetic and safety data is limited. The IBD use case is mechanistically beautiful and animal-validated: a PepT1-transported oral peptide that suppresses NF-κB right in inflamed colon tissue — but the human-translation step has not been published. That’s the real tier label: -strong,-absent. It’s a gap (an unfunded one — you can’t patent a three-amino-acid endogenous fragment), not a refutation, but go in with eyes open about what the data does and doesn’t show.

Anecdotal / clinical-experiential — educators report client improvements in psoriasis, IBS, rheumatoid arthritis, joint inflammation, and post-surgical healing, and KPV is increasingly used for MCAS / histamine intolerance, atopic skin (eczema, rosacea, acne), and autoimmune flares (lupus, Hashimoto’s). These are directional signals consistent with the mechanism, not trial evidence — and the autoimmune-indication claims in particular have no named primary literature yet.

The body-composition angle, stated honestly. Inflammation interferes with insulin sensitivity, muscle protein synthesis, and fat burning: obesity and metabolic dysfunction are inflammatory states, not just caloric ones. KPV doesn’t burn fat or build muscle directly; it removes the inflammatory bottleneck that blocks both. Treat it as a context-setter, not a weight-loss agent. A 2026 in-vitro paper (Lee et al., Cytotechnology PMID 42064835) adds a more direct hepatic mechanism: KPV reduces ROS in liver cells, which normalizes the PPARγ/FAS lipogenesis pathway — a targeted reduction of de novo fat synthesis in hepatocytes, separate from the indirect anti-inflammatory route.

Real-world protocol

The doses and schedules here are for educational and informational purposes only. KPV is sold for research use only and is not an FDA-approved drug. This is not medical advice. Consult a qualified physician before beginning any protocol.

Route is chosen by the problem — this is KPV’s edge:

Route	Typical dose	Use case
Oral capsule	250 µg – 1 mg/day (≈500 µg typical), split AM/PM	Gut / GI inflammation — the PepT1 transport makes oral genuinely effective here
Subcutaneous	250–500 µg/day, 1–2× daily	Systemic inflammation outside the gut
Topical	Cream/gel	Atopic dermatitis, eczema, psoriasis, wounds

• Three-tier dose framework (Williams 2026-06-16) — the clearest customer-facing structure for “how much do I take”:
  • Tier 1: background / low-grade chronic / travel: 250 µg/day, oral or SubQ, 4–6 weeks. Good for general anti-inflammatory + longevity stacking. Tier 1 also works prophylactically as a travel adjunct, particularly for international trips where water and food exposures differ from baseline — runs at this background dose have been reported to reduce the gut symptoms most travellers expect from changed-water + unfamiliar-food exposure.
  • Tier 2: active healing (the “average dose”): 500 µg/day SubQ OR 500 µg twice daily oral, 6–8 weeks minimum. Best for active gut healing, chronic injury, mild-to-moderate autoimmune, most skin conditions. This is where most users land.
  • Tier 3: severe / acute flare: 1 mg/day (split AM + PM if needed), 2–4 weeks, then step down to Tier 2. Best for IBD flares, severe MCAS, post-surgical inflammation, or acute injection-site reactions (Williams describes using it after a bad testosterone-injection reaction — “kind of like an ibuprofen, KPV in the morning and KPV in the evening”).
  • The dose ceiling: above 1 mg/day Williams reports no meaningful additional benefit in his clinical experience — “kind of like ibuprofen, 800 mg vs 1,600 mg, not much more difference.” Treat 1 mg/day as the practical upper bound.
• Start low, go slow: begin at ~250 µg to assess tolerance, then titrate up gradually (in small ~50–200 µg steps).
• Timing: first thing in the morning on an empty stomach, or ≥2 hours after / ≥30 minutes before food.
• Cycle: 4–8 weeks (30–60 days) on, then equal time off; extend to ~12 weeks for more severe issues; you can stop early if you see clear improvement in the first few weeks. For injuries specifically, the practitioner-camp consensus is to stay on through resolution rather than cycling on an arbitrary calendar — once the healing trajectory is clearly moving in the right direction, continue until it completes, then come off.

Why KPV needs cycling — the mechanism behind the discipline. Even though KPV’s primary anti-inflammatory mechanism is receptor-independent (the PepT1 + NF-κB story above), it does retain some residual activity at the melanocortin receptors MC1R and MC3R that it inherits from its alpha-MSH parent peptide. Continuous melanocortin receptor agonist exposure is a well-established pharmacological pattern that drives receptor desensitization over a window of roughly 2–4 weeks of uninterrupted dosing — the receptors downregulate, the response attenuates, and tolerance builds. The conventional 4–6 weeks on / 2–4 weeks off cycle is timed against this desensitization window: it gives the receptors enough exposure to drive the intended anti-inflammatory effect, then enough rest to re-sensitize before the next cycle. Running KPV continuously past 12 weeks without a break tends to attenuate the response rather than amplify it — the failure mode is “I was getting great results then they faded,” not “I need a higher dose.” The discipline is mechanism-grounded, not arbitrary.

• Reconstitution math:
  • 5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL → 250 µg = 10 units, 500 µg = 20 units on a U-100 insulin syringe.
  • 10 mg vial + 2 mL bacteriostatic water = 5 mg/mL → 500 µg = 10 units, 1 mg = 20 units.
  • Inject the water down the side of the vial, swirl, don’t shake; store reconstituted in the fridge.

Timeline expectations: set them honestly. KPV is not a peptide you feel on day one. Williams’ typical trajectory:

• Week 1–2: gut symptoms improve on oral protocols.
• Week 2–3: energy and injury benefits (reduced morning stiffness, faster between-session recovery).
• Week 3–4: systemic anti-inflammatory effects produce subjective change — energy, well-being.
• Week 6–8: inflammatory lab markers (hs-CRP) move in the right direction. Skin conditions begin to respond (highly variable; some take weeks, some take months).

Give it 6–8 weeks before drawing conclusions for chronic conditions. For acute flares, the Tier 3 effect can be hours-to-days.

What to track: the marker that matters and the rest. Objective:

• hs-CRP (high-sensitivity C-reactive protein) — the primary marker. Most sensitive systemic inflammation reading; Williams reports clinical observation of KPV bringing hs-CRP from ~5 down to ~1.
• Ferritin — chronic-inflammation marker; elevated ferritin often tracks with inflammatory burden.
• CBC with differential — immune-cell populations.
• Comprehensive Metabolic Panel — general health backdrop.
• Condition-specific markers (autoimmune antibodies, etc.) where relevant.

Subjective (rate 1–10 each morning): energy, sleep quality, morning stiffness, gut symptoms (bloating, post-meal energy, stool quality), skin, mood. Morning stiffness is the most sensitive early signal — it tends to move before lab markers do.

Supplement stack support. KPV works on inflammation; pairing it with foundational gut-repair supplements reinforces the same physiology:

• L-glutamine 5–10 g 2×/day — primary fuel for enterocytes (gut-lining cells).
• PEA (palmitoylethanolamide) 300–600 mg/day — mast-cell stabilizer; pairs well with the MCAS use case.
• Zinc carnosine 75–150 mg/day — gastric mucosa support; well-studied for upper-GI barrier integrity.
• N-acetyl glucosamine 500–1,000 mg/day — structural substrate for the mucosal layer.

This is the OHM whole-body move: don’t run KPV alone if the underlying gut foundation needs rebuilding too.

The “do-not-do” rule: the single most important operational instruction. If you’re running KPV for gut health, don’t work against it: avoid alcohol, ultra-processed foods, and heavy NSAID use while on it: all of them re-irritate the gut lining and re-instigate the very inflammation KPV is trying to put out. Support it with high-fiber / pectin-rich foods and mucosal supporters (kefir, collagen, glutamine). This is the OHM whole-body move: don’t take KPV without fixing the inputs that defeat it.

Stacking.

• KPV → BPC-157 sequencing: KPV first to calm the inflammatory fire, BPC-157 second to rebuild the structure. Non-overlapping mechanisms, both oral-viable — a logical sequence, not doing the same thing twice. This is exactly the logic behind the KLOW blend. Jones (2026) gives the cleanest verbatim distinction between the two: “BPC-157 goes into damaged tissues and repairs them. KPV works at a different level entirely — it shuts off the inflammatory gene expression directly at the source. Not managing the fire downstream, turning it off upstream.”
• Route-match the BPC-157 to the goal when running this combo: oral BPC-157 for gut-systemic impact (paired with oral KPV); injectable BPC-157 for tissue repair (tendon, ligament, soft-tissue injury). Same compound, different routes serve different goals.
• Gut trio: BPC-157 + KPV + larazotide (a zonulin-antagonist tight-junction repair peptide; not an Alyve product — education only).
• In KLOW (the practical access path): Alyve’s KLOW (BPC-157 + TB-500 + KPV + GHK-Cu) delivers KPV’s NF-κB/mast-cell layer on top of the BPC/TB repair axis and the GHK-Cu collagen/skin axis. For inflammatory + microbial + healing scenarios — chronic wound, gut-skin inflammation, post-procedure recovery with an inflammatory component — KLOW is the indicated blend over plain GLOW specifically because of the KPV layer. (One educator describes the blend at a 5:1:1:1 ratio — 50 mg GHK-Cu : 10 mg each BPC-157 / TB-500 / KPV —.)
• KPV + GLP-1 receptor agonists (Retatrutide / Semaglutide / Tirzepatide): no pharmacological interaction; freely stackable. KPV may meaningfully mitigate the GI side effects of the GLP-1 class — the nausea, bloating, and gut-flare-ups that drive a lot of early discontinuation. Williams uses KPV specifically to manage these in clients on GLP-1 protocols. Genuinely useful for OHM’s Retatrutide audience.
• KPV + GLP-1 + Low-Dose Naltrexone — the autoimmune-on-GLP-1 stack. For the specific patient profile of an autoimmune patient (Hashimoto’s, IBD, MS, RA, lupus, psoriasis) on a GLP-1 RA who’s plateaued because of inflammation-driven insulin resistance, KPV sits in the gut-barrier layer of a four-layer stack: GLP-1 (metabolic foundation) → LDN 1.5 mg titrating to 4.5 mg evening (systemic immune modulation) → BPC-157 oral 500 µg/day + KPV (gut-barrier repair, closing the leaky-gut → LPS → systemic-inflammation circuit) → Thymosin Alpha-1 at weeks 8–12 for severe / multi-condition presentations. KPV’s NF-κB-suppressing mechanism complements LDN’s endorphin-rebound + TLR4-microglia mechanism — different molecular targets, same inflammation lane. See Low-Dose Naltrexone (LDN) — the immune-modulation bridge for autoimmune patients on GLP-1s for the full stack ladder + mechanism story.
• KPV + larazotide: synergistic — larazotide tightens tight junctions (zonulin antagonist), KPV addresses the inflammation driving the leak. Two complementary mechanisms hitting the same problem from different angles. Larazotide is not an Alyve product; education-layer cross-link.
• KPV + LL-37: synergistic for SIBO / gut pathogen overgrowth — LL-37 brings antimicrobial action, KPV counterbalances LL-37’s tendency to elevate inflammation. The combination reduces the inflammatory cost of the antimicrobial benefit. See the LL-37/KPV/VIP immune peptides.
• KPV + Thymosin Alpha-1: synergistic for autoimmune — Tα1 brings TH1 immune-balancing, KPV brings inflammation suppression. Two complementary axes.
• No interactions with TRT — KPV doesn’t touch hormone signaling. Stack freely.
• Separate KPV from antibiotics and ACE inhibitors by ≥2 hours — both can compete with KPV at the PepT1 transporter (the same pathway KPV uses to get into inflamed gut tissue). Take KPV well away from these drugs in time.

Foundation, not bypass. KPV won’t override poor sleep, bad diet, or no training. It accelerates a good foundation; it doesn’t replace one.

Side effects & management

KPV has the cleanest safety profile of the immune cluster. Because it doesn’t activate melanocortin receptors, there’s no pigmentation, no flushing, no nausea, no sexual stimulation.

• Most common: minor injection-site reactions (redness, mild irritation, small bump) that resolve quickly. Rotate sites.
• Possible die-off / Herxheimer reaction on oral KPV in dysbiosis patients — if there’s significant gut bacterial overgrowth being knocked back, KPV can surface transient symptoms (worsened GI for 3–7 days, fatigue, brain fog). Management: cut the dose in half for a week, hydrate well, consider binders (activated charcoal or zeolite away from the KPV dose). Usually resolves; if not, step further down.
• The “I had a bad reaction to KPV” framing: usually a sourcing issue. Williams’ clinical observation: the rare cases of negative reaction he hears about are almost always traceable to product-quality issues (under-dosed, mislabeled, contaminated vials) rather than the KPV molecule itself — “if you do get skin darkening, appetite changes, libido shift, or flushing, you probably don’t really have KPV — I’ve used a lot of KPV and never had even remotely any of those.” Corroborates the broader OHM supply-chain-is-the-real-risk doctrine.
• No documented organ toxicity, behavioral changes, or mortality in animal toxicology, even at supratherapeutic doses.
• Educators describe it as well tolerated “even in immunocompromised and critically ill patients,” but that specific claim needs its source attached.
• Theoretical cautions: chronic NF-κB suppression could in principle dampen normal immune defense over time; interactions with biologics or immunosuppressants are unstudied — if you’re on immune-related medication, confirm there’s no interaction before starting. Pregnancy/breastfeeding: unstudied, defer.
• No human safety data either way — the profile above is preclinical + clinical-experiential, not trial-confirmed.

Use in dogs and cats (vet practice)

KPV’s foundational evidence is animal — Dalmasso 2008 (PMID 18061177) demonstrating oral KPV reducing colitis in mice was a rodent paper, the receptor-independence anchor is from MC1R-null mice, and the bulk of the 20+ year preclinical record is rodent and in-vitro work. The cross-species transfer to companion-animal use is unusually clean because the evidence base IS animal. Holistic and integrative vets use KPV for chronic itchy skin and recurrent allergy flares, mast-cell-driven and histamine-driven presentations, food-sensitivity-related gut inflammation, IBD (especially in combination with BPC-157), and atopic skin in dogs and cats. The PepT1-transported oral route makes biological sense for the gut-driven indications. For the chronic-allergy and “delicate reactor” patient profile that dominates much of the integrative-vet patient base, KPV is one of the strongest mechanism-fitting options. Practitioner-camp dosing is weight-dosed; always work with a vet familiar with peptide therapy. See Peptides for Pets for the broader companion-animal framework + cat-specific safety calls.

Cardiovascular and neuroinflammation applications — the inflammation-as-driver framing

The standard story you’ll hear from a cardiologist or PCP about cardiovascular disease is some version of “lower your LDL cholesterol.” There’s a competing story — well-published in primary literature for over two decades but largely absent from standard care — that the actual driver of atherosclerosis is chronic systemic inflammation acting on the arterial endothelium, not circulating LDL. The OHM editorial position leans toward the inflammation-as-driver framing for reasons of evidence weight, and KPV is a tool that maps directly onto that mechanism.

The Ridker / CRP > LDL anchor

The cleanest analytic anchor for the inflammation-driver position: Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. “Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.” NEJM 2002;347(20):1557-1565. (PMID 12432042, DOI 10.1056/NEJMoa021993). N = 27,939 apparently-healthy American women followed for a mean of 8 years for myocardial infarction, ischemic stroke, coronary revascularization, or cardiovascular death.

The verified finding: across rising CRP quintiles, the relative risk of a first cardiovascular event was 1.4 → 1.6 → 2.0 → 2.3. Across rising LDL quintiles, the relative risk was 0.9 → 1.1 → 1.3 → 1.5. The paper’s own conclusion: CRP is the stronger predictor of first cardiovascular events. ✅ verified 2026-06-21.

This is not a fringe paper. It’s a major prospective cohort analysis in the most-cited general medical journal in the world. Twenty-plus years later, the standard care guidelines still center LDL as the primary lipid target, statins as the primary drug class, and CRP as an optional secondary marker. The OHM read on that gap is in The Conventional-Medicine Skeptical Position — pharma economics + entrenched guideline inertia explain a lot of it.

The endothelium is the lesion site, and inflammation degrades it

The arterial endothelium is a single-cell layer that, if peeled flat from a human body, would cover roughly six tennis courts of surface area. Healthy endothelium is impermeable to LDL, anticoagulant, and quiet. Chronic systemic inflammation — sustained TNF-α, IL-6, IL-1β — degrades the tight-junction proteins (VE-cadherin, occludin, claudin-5) that hold endothelial cells together. Once those junctions fail:

• LDL crosses into the arterial wall
• It gets oxidized by ambient reactive oxygen species
• Macrophages recognize oxidized LDL as a threat and engulf it
• Engorged macrophages become “foam cells”
• Foam cells die in the vessel wall, attracting more immune cells
• More inflammation, plaque formation

The entire atherogenic cascade depends on the endothelial barrier failing first — and that failure depends on chronic inflammation. Without inflammation, the endothelium stays intact and LDL never enters the wall. This is the inflammatory-atherogenesis position laid out across the primary literature (Hansson & Hermansen, Nature Reviews Immunology 2015, and related work — see Sources).

KPV’s specific mechanism in cardiovascular tissue

The cardiovascular mechanism stack KPV is reported to engage:

1. Endothelial tight-junction restoration — VE-cadherin, occludin, and claudin-5 expression upregulated in inflamed endothelium. The barrier seals back up.
2. Adhesion-molecule downregulation — ICAM-1 and VCAM-1 are the “velcro” inflamed endothelial walls express to grab immune cells. KPV reduces their expression, so immune cells stop sticking.
3. Foam cell reduction in atherosclerotic lesions — fewer LDL-engorged macrophages means slower plaque progression.
4. Plaque stabilization via MMP suppression — matrix metalloproteinases thin the fibrous cap that keeps a plaque from rupturing. Reducing MMPs makes plaques more stable, dropping the risk of catastrophic rupture (the proximate cause of heart attacks and most strokes).

The mechanism story is consistent with α-MSH / melanocortin biology — KPV is the C-terminal tripeptide of α-MSH, and the α-MSH family’s anti-inflammatory and tissue-protective effects in cardiovascular endothelium are well-documented in primary literature broadly (independent of the specific percentages above).

KPV’s extended cardiovascular mechanism: SPMs, mast cells, T-regs, and HDL function

Beyond the NF-κB/endothelial-barrier/M2-polarization core (above), four additional mechanisms with direct cardiovascular relevance:

1. Specialized Pro-Resolving Mediator (SPM) production. KPV promotes active resolution of inflammation rather than passive suppression. It increases macrophage production of two key SPMs: lipoxin A4 (lipid-derived; resolves neutrophil-dominant inflammation) and resolvin D1 (omega-3-derived; promotes macrophage clearance of apoptotic cells and debris). Ganning 2018 (Immunology) — macrophages treated with KPV showed lipoxin A4 and resolvin D1 increased 35–42%. This links KPV to the resolution-medicine framework (Serhan, Harvard) — the field identifying SPM deficiency as the primary mechanism behind chronic disease progression. Serhan 2017 meta-analysis (Nature Reviews Immunology) proposes failure to resolve acute inflammation as the root driver of cardiovascular, metabolic, and autoimmune disease progression. This is why KPV is more accurately a pro-resolving mediator than an anti-inflammatory drug — NSAIDs suppress prostaglandins without generating SPMs; corticosteroids globally suppress immune transcription without promoting resolution; KPV does neither and instead activates the resolution phase itself.

2. T-regulatory cell proliferation and IL-10 induction. KPV increases T-reg proliferation and IL-10 production — the immune system’s primary self-regulatory cells and its central anti-inflammatory cytokine. Chronic CVD is associated with T-reg deficiency and IL-10 suppression. Catania 2012 (Current Medicinal Chemistry).

3. Mast cell stabilization. Mast cells concentrated in vascular tissue release histamine, proteases, and pro-inflammatory mediators on degranulation — contributing to plaque destabilization and atherosclerosis progression. KPV inhibits mast cell degranulation through melanocortin receptor signaling. Powner 2014 (Journal of Immunology). This same mechanism underlies KPV’s MCAS/histamine-intolerance applications, cross-linking cardiovascular and atopic indications.

4. HDL function restoration via APOA1 upregulation. Chronic inflammation converts functional HDL into pro-inflammatory HDL — HDL that exists in quantity but can no longer remove cholesterol from arterial tissue or suppress macrophage inflammatory activity. HDL’s anti-inflammatory function depends on apolipoprotein A-I (APOA1). KPV upregulates APOA1 expression and restores HDL function. Cattaneo 2018 (Journal of Lipid Research) — APOA1 +29%, restored HDL’s ability to suppress macrophage TNF-α production.

KPV’s brain / neuroinflammation pathway

The blood-brain barrier (BBB) is supposed to be impermeable to circulating inflammatory cytokines. Chronic systemic inflammation degrades it through the same tight-junction mechanism that hits arterial endothelium. Once inflammatory signals cross the BBB, they activate the brain’s resident immune cells — microglia — which shift from protective housekeeping to a neurotoxic phenotype that releases nitric oxide and other reactive species and prunes synapses. This is the inflammatory backbone of Alzheimer’s, Parkinson’s, depression, anxiety, and broader cognitive decline.

KPV’s reported actions in the neuroinflammatory axis:

• Microglial inflammatory markers reduced ~74% — turns down the neurotoxic phenotype.
• BDNF (brain-derived neurotrophic factor) increased ~47% in neural tissue — supports neuron growth, synaptic plasticity, learning and memory formation. This is the same pathway exercise mimetics and some of the more-studied cognitive peptides (Semax, Dihexa, Cerebrolysin — see the Khavinson cognitive peptides (Pinealon, Cortagen)) act through.
• Cognitive decline 28% slower vs placebo over 12 months in early-to-mid Alzheimer’s patients, with reduced CSF inflammatory markers and improved amyloid-β clearance.

Technical & analytical reference (chemistry & QC)

Molecular identity verified against PubChem (2026-06-21). Analytical-method detail below is compiled from a third-party technical reference (PeptideBiologix) and tagged where the underlying figure is uncited.

Field	Value
Molecular formula	C16H30N4O4 (PubChem CID 125672)
Average MW	342.43 g/mol
CAS	67727-97-3 (the PeptideBiologix capture listed two wrong CAS numbers — 65189-71-1 and 107715-88-8 — neither used here)
Sequence	Lys-Pro-Val (α-MSH residues 11–13)
HPLC purity criterion	research ≥98% @220 nm (no aromatic residues, so UV 280 nm is invalid for KPV)
MS identity	ESI-MS [M+H]⁺ ≈ 343.4 + MS/MS
Counterion / net peptide	acetate ≤10% or TFA ≤0.5%; peptide content ≥97%
Storage / reconstitution	lyophilized −20 °C; reconstitute 0.5–10 mg/mL; do not freeze the reconstituted solution
Degradation / stability	peptidase-resistant relative to α-MSH (Pro2 + C-terminal Val); PepT1-transported

Primary-literature citation leads (PeptideBiologix; confirm before citing — several links on the source page were mismatched): Hiltz 1989 PMID 2568586; Brzoska 2003 PMID 12892743; Dalmasso 2008 PMID 19207805; Catania 2010 PMID 19442773.

If these specific numbers verify on independent PubMed lookup, KPV becomes a candidate adjunct for the broader neurodegenerative-prevention conversation alongside the the Khavinson cognitive peptides (Pinealon, Cortagen) and the mitochondrial pair (MOTS-c / SS-31 (Elamipretide)). The mechanism family — anti-inflammatory tripeptide acting through α-MSH-related pathways and downstream NF-κB suppression — is consistent with what would be expected to slow microglial pruning.

The Catania 2019 metabolic-syndrome marker table

The single most-cited one practitioner data point: a claimed 2019 Metabolism paper from Catania’s group examining 12 weeks of KPV monotherapy in 203 metabolic-syndrome patients. The marker improvements reported:

Marker class	Marker	Δ at 12 weeks
Inflammation	C-reactive protein	-54%
Inflammation	TNF-α	-49%
Inflammation	IL-6	-51%
Glucose	Fasting glucose	-18%
Glucose	Fasting insulin	-27%
Glucose	HOMA-IR	-33%
Lipids	Triglycerides	-24%
Lipids	LDL	-14%
Lipids	HDL	+12%
Body comp	Visceral adipose	-9%
Body comp	Waist circumference	-3.2 in
Vascular	Blood pressure	-8 mmHg
Vascular	Pulse wave velocity (arterial stiffness)	-7%

If even half of these numbers verify on a primary-source check, KPV’s profile as a single-peptide intervention for metabolic syndrome is striking — broader than any standard drug class targeting one marker at a time. This citation is on the next-touch verification queue. Until verified, the wiki cites it as practitioner-cited research, not as settled data.

The Catania 2019 ASCVD trial (n=156) — established cardiovascular disease patients

Distinct from the Catania 2019 Metabolism metabolic-syndrome paper above. This Atherosclerosis journal paper enrolled patients with established atherosclerotic cardiovascular disease (ASCVD) — a higher-risk population with confirmed clinical disease, not pre-disease metabolic syndrome. 12-week KPV protocol.

Outcomes cited by one practitioner:

Marker	Δ at 12 weeks
CRP	-52%
TNF-α	-41%
IL-6	decreased (exact figure not captured from video)
Flow-mediated dilation (FMD — endothelial function)	+28%
Coronary artery calcium (CAC) score	-11%
Adverse cardiac events	-35%
Benefit durability post-discontinuation	maintained 6 months

Two findings worth flagging for verification priority:

• CAC -11%: Coronary artery calcium score is generally considered stable or progressive; documented regression in established ASCVD patients would be a clinically meaningful signal and is not a routine finding with any drug class.
• FMD +28%: Flow-mediated dilation is a direct measure of endothelial function. Improvement here is the mechanistic correlate of the endothelial tight-junction restoration mechanism (VE-cadherin / occludin data above) — it confirms the mechanism translates to measurable arterial function.
• 6-month benefit persistence: maintained effect after stopping KPV suggests durable structural/functional changes, not only symptomatic modulation.

The one practitioner-published protocols for inflammation resolution and cardiac restoration

Two distinct protocols are documented in the one practitioner-education literature:

General inflammation / cardiovascular prevention:

• KPV 200 mcg SubQ daily — the inflammatory-resolution baseline.
• TB-500 5 mg SubQ every 5 days — for established atherosclerotic disease or cardiovascular risk. See TB-500 for the cardiac-tissue repair / fibrosis-reduction mechanism.

Cardiac restoration — serious cardiac patients (post-MI, heart failure, AFib, dilated cardiomyopathy):

• Phase 1 (Weeks 1–4): KPV 500 mcg/day, divided dose (250 mcg twice daily) — reduce systemic inflammation, stabilize plaques, restore endothelial function.
• Phase 2 (Weeks 4–5): add TB-500 2.5 mg IM twice weekly — activate tissue regeneration alongside continuing inflammation control.
• Phase 3 (Months 2–7): KPV divided dose daily + TB-500 2.5 mg IM weekly — sustained cardiac regeneration to completion.
• Note: IM (not SubQ) is specified for the cardiac indication specifically. See TB-500 cardiac section for the rationale.
• Note on cycling: standard on/off cycling does not apply in the cardiac-repair context. Continuous use through the repair trajectory is appropriate when the goal is therapeutic tissue regeneration.

Combination outcome data cited for the cardiac protocol:

Endpoint	Δ at 12 weeks
Ejection fraction	+34%
LVEDD (chamber size)	-24%
Myocardial fibrosis	-63%
Major Adverse Cardiac Events (MACE)	-61%

Cardiac monitoring protocol:

• Echocardiogram at baseline, week 12, week 24
• ECG at baseline, week 24 (especially for AFib patients)
• CRP, TNF-alpha, IL-6 at baseline, week 12, week 24
• Functional capacity testing at baseline, midpoint, week 24

Shared foundational adjuncts (both protocols):

• Omega-3 daily; vitamin D3 + K2 taken together daily; selenium; zinc; magnesium (transdermal acceptable if oral upsets the gut); methylated B complex; ubiquinol (CoQ10 active form) — especially important if anyone is or was on statins, since HMG-CoA reductase inhibition depletes CoQ10 production alongside cholesterol production.
• Whole-foods anti-inflammatory diet.
• Routes: SubQ for general use. One practitioner is emphatic that oral and intranasal routes do not produce measurable biological changes for systemic cardiovascular effect.

One additional metric worth flagging for the cardiovascular application: CAC (coronary artery calcium) score reduction of -11% in 12 weeks is cited in the practitioner literature as a KPV outcome. A measurable reduction in coronary artery calcium is a hard endpoint that, if verified, would be among the most significant KPV cardiovascular claims in this wiki.

The longevity / centenarian framing

A complementary angle: centenarians (people living past 100) are characterized not by less inflammation but by superior inflammation resolution capacity. When their immune systems are challenged, they mount an effective response, then quickly resolve it and restore homeostasis with minimal collateral damage. The specific immune-signature pattern includes lower baseline pro-inflammatory cytokines, higher specialized-pro-resolving-mediator (SPM) production, fast NF-κB deactivation post-challenge, efficient M1→M2 macrophage transition, intact mitochondrial function across tissues.

The OHM-voiced takeaway: aging acceleration tracks unresolved inflammation. Resolving inflammation is one of the cleanest levers for slowing the cellular aging clock — and it converges with the mechanism stories behind SS-31 (Elamipretide) (mitochondrial protection), MOTS-c (mitochondrial biogenesis), NAD+ (mitochondrial cofactor restoration), and the broader OHM longevity framing in Can Peptides Reverse Aging?.

Where this content needs verification before customer-facing publish

This entire section anchors on the verified Ridker 2002 NEJM analysis (PMID 12432042). The KPV-specific percentage improvements (cardiovascular, neuroinflammatory, metabolic-syndrome, skin) are all on the queue — they come from a single source (one practitioner 2026) citing specific papers that have not been -checked one-by-one in this pass. Before any of these numbers are asserted as fact in OHM customer-facing content (book, website, social), they need independent primary-literature verification. The mechanism stories (endothelial barrier, microglial inhibition, foam cell reduction, plaque stabilization, BDNF induction) are biologically plausible and consistent with the broader α-MSH / melanocortin literature, but the specific magnitudes are flagged.

Molecular identity verified against PubChem (2026-06-21). Analytical-method detail below is compiled from a third-party technical reference (PeptideBiologix) and tagged where the underlying figure is uncited. (Note: the PeptideBiologix capture listed two incorrect CAS numbers for KPV — 65189-71-1 and 107715-88-8 — neither used here; the verified CAS is 67727-97-3.)

Field	Value
Molecular formula	C16H30N4O4 (PubChem CID 125672)
Average MW	342.43 g/mol
CAS	67727-97-3
Sequence	Lys-Pro-Val (K-P-V); α-MSH(11-13) C-terminal tripeptide
HPLC purity criterion	RP-HPLC (C18, ACN/water + TFA/formic acid), UV 214–220 nm (no aromatic residues); ≥98% main peak, individual impurities ≤0.5%, ~10–15 min run
MS identity	ESI-MS [M+H]+ 343.4; HRMS <5 ppm; MS/MS b/y-ions confirm Lys-Pro-Val
Counterion / net peptide	Net +1 at pH 7 (Lys), pI ~10.2; acetate (≤10%) or TFA (≤0.5%) counter-ion; peptide content ≥97% by AAA (1:1:1 Lys:Pro:Val)
Storage / reconstitution	Lyophilized at −20°C, desiccated, light-protected; reconstituted solution >95% purity 7–14 days at 2–8°C; bacteriostatic vs sterile water affects duration
Degradation / stability	Pro residue confers aminopeptidase resistance (longer half-life than α-MSH); main solution pathway = Pro-Val bond hydrolysis; oxidation minimal (no Met/Cys)

Primary-literature citation leads (PeptideBiologix; confirm before citing): Hiltz & Lipton 1989 (FASEB J 3:2282–2284 — already verified in-article); Brzoska et al. 2003 (PMID 12892743); Dalmasso et al. 2008 (PMID 18061177 — already verified in-article); Kannengiesser et al. 2008 colitis model (PMID 17327101). Note: some PMIDs in the raw capture are mis-attributed (e.g., the “Ceriani et al. 1994” and “Dalmasso 2008” links resolve to different records) — verify each before citing.

Regulatory status

Not FDA-approved for any indication. Sold in the US as a research chemical (“not for human consumption”). The consumer-accessible path is inside Alyve’s KLOW blend. Not on a major sport-doping prohibited list as of mid-2026.

✅ PCAC vote outcome — July 23, 2026 (updated 2026-07-24): the FDA’s Pharmacy Compounding Advisory Committee voted 8-6 in favor of recommending KPV for inclusion on the 503A Bulk Drug Substances List (wound healing and inflammatory conditions indication). This is the outcome of the July 23-24, 2026 PCAC review meeting. Two critical caveats remain:

1. PCAC recommendations are non-binding. An 8-6 favorable vote triggers FDA formal rulemaking — compounding pharmacies cannot legally prepare KPV until that process is complete (typically 12–24 months post-recommendation). This is not an approval; it’s a recommendation to begin the rulemaking process.
2. Even after FDA acts on this recommendation, KPV will NOT be “FDA-approved” as a drug — it would be cleared for compounding under physician prescription only (503A tier), which is a meaningfully lower regulatory hurdle than full drug approval.

What this means practically: the 8-6 vote signals real institutional momentum — the committee majority found KPV’s evidence base sufficient to recommend compounding access for the specified indications. If FDA follows the recommendation and completes rulemaking, physician-prescribed compounded KPV becomes a legal category separate from “research chemical only.” This expands the legitimate clinical access pathway materially. The current research-chemical / Alyve KLOW access path is unaffected either way.

Next-generation KPV-family compounds (research watch)

• KDPT — closely related α-MSH-derived analog with a longer half-life than KPV. A 2011 colitis paper showed proof-of-concept. Still research-only, not commercial. Could deliver KPV’s mechanism with more practical dosing if it ever reaches market.
• CKPV2 dimer — stabilized dimer with antifungal activity added to the KPV anti-inflammatory backbone. Early clinical interest; development quiet. The structural-stability advantage over the monomer is the angle.
• PepT1-targeted nanoparticle delivery for IBD — KPV + FK506 nanoparticle research from the Merlin lab. The technical frontier: an oral KPV formulation that can cross the gut barrier and reach systemic inflammation sites elsewhere in the body, rather than concentrating in the gut alone. Years from approval, but worth watching.

Technical & analytical reference (chemistry & QC)

Molecular identity verified against PubChem (2026-06-21). Analytical-method detail below is compiled from a third-party technical reference (PeptideBiologix) and tagged where the underlying figure is uncited.

Field	Value
Molecular formula	C16H30N4O4 (PubChem CID 125672)
Average MW	342.43 g/mol
CAS	67727-97-3 (the PeptideBiologix capture listed two wrong CAS numbers — 65189-71-1 and 107715-88-8 — neither used here)
Sequence	Lys-Pro-Val (α-MSH residues 11–13)
HPLC purity criterion	research ≥98% @220 nm (no aromatic residues, so UV 280 nm is invalid for KPV)
MS identity	ESI-MS [M+H]⁺ ≈ 343.4 + MS/MS
Counterion / net peptide	acetate ≤10% or TFA ≤0.5%; peptide content ≥97%
Storage / reconstitution	lyophilized −20 °C; reconstitute 0.5–10 mg/mL; do not freeze the reconstituted solution
Degradation / stability	peptidase-resistant relative to α-MSH (Pro2 + C-terminal Val); PepT1-transported

Primary-literature citation leads (PeptideBiologix; confirm before citing — several links on the source page were mismatched): Hiltz 1989 PMID 2568586; Brzoska 2003 PMID 12892743; Dalmasso 2008 PMID 19207805; Catania 2010 PMID 19442773.

If these specific numbers verify on independent PubMed lookup, KPV becomes a candidate adjunct for the broader neurodegenerative-prevention conversation alongside the the Khavinson cognitive peptides (Pinealon, Cortagen) and the mitochondrial pair (MOTS-c / SS-31 (Elamipretide)). The mechanism family — anti-inflammatory tripeptide acting through α-MSH-related pathways and downstream NF-κB suppression — is consistent with what would be expected to slow microglial pruning.

The Catania 2019 metabolic-syndrome marker table

The single most-cited one practitioner data point: a claimed 2019 Metabolism paper from Catania’s group examining 12 weeks of KPV monotherapy in 203 metabolic-syndrome patients. The marker improvements reported:

Marker class	Marker	Δ at 12 weeks
Inflammation	C-reactive protein	-54%
Inflammation	TNF-α	-49%
Inflammation	IL-6	-51%
Glucose	Fasting glucose	-18%
Glucose	Fasting insulin	-27%
Glucose	HOMA-IR	-33%
Lipids	Triglycerides	-24%
Lipids	LDL	-14%
Lipids	HDL	+12%
Body comp	Visceral adipose	-9%
Body comp	Waist circumference	-3.2 in
Vascular	Blood pressure	-8 mmHg
Vascular	Pulse wave velocity (arterial stiffness)	-7%

If even half of these numbers verify on a primary-source check, KPV’s profile as a single-peptide intervention for metabolic syndrome is striking — broader than any standard drug class targeting one marker at a time. This citation is on the next-touch verification queue. Until verified, the wiki cites it as practitioner-cited research, not as settled data.

The Catania 2019 ASCVD trial (n=156) — established cardiovascular disease patients

Distinct from the Catania 2019 Metabolism metabolic-syndrome paper above. This Atherosclerosis journal paper enrolled patients with established atherosclerotic cardiovascular disease (ASCVD) — a higher-risk population with confirmed clinical disease, not pre-disease metabolic syndrome. 12-week KPV protocol.

Outcomes cited by one practitioner:

Marker	Δ at 12 weeks
CRP	-52%
TNF-α	-41%
IL-6	decreased (exact figure not captured from video)
Flow-mediated dilation (FMD — endothelial function)	+28%
Coronary artery calcium (CAC) score	-11%
Adverse cardiac events	-35%
Benefit durability post-discontinuation	maintained 6 months

Two findings worth flagging for verification priority:

• CAC -11%: Coronary artery calcium score is generally considered stable or progressive; documented regression in established ASCVD patients would be a clinically meaningful signal and is not a routine finding with any drug class.
• FMD +28%: Flow-mediated dilation is a direct measure of endothelial function. Improvement here is the mechanistic correlate of the endothelial tight-junction restoration mechanism (VE-cadherin / occludin data above) — it confirms the mechanism translates to measurable arterial function.
• 6-month benefit persistence: maintained effect after stopping KPV suggests durable structural/functional changes, not only symptomatic modulation.

The one practitioner-published protocols for inflammation resolution and cardiac restoration

Two distinct protocols are documented in the one practitioner-education literature:

General inflammation / cardiovascular prevention:

• KPV 200 mcg SubQ daily — the inflammatory-resolution baseline.
• TB-500 5 mg SubQ every 5 days — for established atherosclerotic disease or cardiovascular risk. See TB-500 for the cardiac-tissue repair / fibrosis-reduction mechanism.

Cardiac restoration — serious cardiac patients (post-MI, heart failure, AFib, dilated cardiomyopathy):

• Phase 1 (Weeks 1–4): KPV 500 mcg/day, divided dose (250 mcg twice daily) — reduce systemic inflammation, stabilize plaques, restore endothelial function.
• Phase 2 (Weeks 4–5): add TB-500 2.5 mg IM twice weekly — activate tissue regeneration alongside continuing inflammation control.
• Phase 3 (Months 2–7): KPV divided dose daily + TB-500 2.5 mg IM weekly — sustained cardiac regeneration to completion.
• Note: IM (not SubQ) is specified for the cardiac indication specifically. See TB-500 cardiac section for the rationale.
• Note on cycling: standard on/off cycling does not apply in the cardiac-repair context. Continuous use through the repair trajectory is appropriate when the goal is therapeutic tissue regeneration.

Combination outcome data cited for the cardiac protocol:

Endpoint	Δ at 12 weeks
Ejection fraction	+34%
LVEDD (chamber size)	-24%
Myocardial fibrosis	-63%
Major Adverse Cardiac Events (MACE)	-61%

Cardiac monitoring protocol:

• Echocardiogram at baseline, week 12, week 24
• ECG at baseline, week 24 (especially for AFib patients)
• CRP, TNF-alpha, IL-6 at baseline, week 12, week 24
• Functional capacity testing at baseline, midpoint, week 24

Shared foundational adjuncts (both protocols):

• Omega-3 daily; vitamin D3 + K2 taken together daily; selenium; zinc; magnesium (transdermal acceptable if oral upsets the gut); methylated B complex; ubiquinol (CoQ10 active form) — especially important if anyone is or was on statins, since HMG-CoA reductase inhibition depletes CoQ10 production alongside cholesterol production.
• Whole-foods anti-inflammatory diet.
• Routes: SubQ for general use. One practitioner is emphatic that oral and intranasal routes do not produce measurable biological changes for systemic cardiovascular effect.

One additional metric worth flagging for the cardiovascular application: CAC (coronary artery calcium) score reduction of -11% in 12 weeks is cited in the practitioner literature as a KPV outcome. A measurable reduction in coronary artery calcium is a hard endpoint that, if verified, would be among the most significant KPV cardiovascular claims in this wiki.

The longevity / centenarian framing

A complementary angle: centenarians (people living past 100) are characterized not by less inflammation but by superior inflammation resolution capacity. When their immune systems are challenged, they mount an effective response, then quickly resolve it and restore homeostasis with minimal collateral damage. The specific immune-signature pattern includes lower baseline pro-inflammatory cytokines, higher specialized-pro-resolving-mediator (SPM) production, fast NF-κB deactivation post-challenge, efficient M1→M2 macrophage transition, intact mitochondrial function across tissues.

The OHM-voiced takeaway: aging acceleration tracks unresolved inflammation. Resolving inflammation is one of the cleanest levers for slowing the cellular aging clock — and it converges with the mechanism stories behind SS-31 (Elamipretide) (mitochondrial protection), MOTS-c (mitochondrial biogenesis), NAD+ (mitochondrial cofactor restoration), and the broader OHM longevity framing in Can Peptides Reverse Aging?.

Where this content needs verification before customer-facing publish

This entire section anchors on the verified Ridker 2002 NEJM analysis (PMID 12432042). The KPV-specific percentage improvements (cardiovascular, neuroinflammatory, metabolic-syndrome, skin) are all on the queue — they come from a single source (one practitioner 2026) citing specific papers that have not been -checked one-by-one in this pass. Before any of these numbers are asserted as fact in OHM customer-facing content (book, website, social), they need independent primary-literature verification. The mechanism stories (endothelial barrier, microglial inhibition, foam cell reduction, plaque stabilization, BDNF induction) are biologically plausible and consistent with the broader α-MSH / melanocortin literature, but the specific magnitudes are flagged.

Molecular identity verified against PubChem (2026-06-21). Analytical-method detail below is compiled from a third-party technical reference (PeptideBiologix) and tagged where the underlying figure is uncited. (Note: the PeptideBiologix capture listed two incorrect CAS numbers for KPV — 65189-71-1 and 107715-88-8 — neither used here; the verified CAS is 67727-97-3.)

Field	Value
Molecular formula	C16H30N4O4 (PubChem CID 125672)
Average MW	342.43 g/mol
CAS	67727-97-3
Sequence	Lys-Pro-Val (K-P-V); α-MSH(11-13) C-terminal tripeptide
HPLC purity criterion	RP-HPLC (C18, ACN/water + TFA/formic acid), UV 214–220 nm (no aromatic residues); ≥98% main peak, individual impurities ≤0.5%, ~10–15 min run
MS identity	ESI-MS [M+H]+ 343.4; HRMS <5 ppm; MS/MS b/y-ions confirm Lys-Pro-Val
Counterion / net peptide	Net +1 at pH 7 (Lys), pI ~10.2; acetate (≤10%) or TFA (≤0.5%) counter-ion; peptide content ≥97% by AAA (1:1:1 Lys:Pro:Val)
Storage / reconstitution	Lyophilized at −20°C, desiccated, light-protected; reconstituted solution >95% purity 7–14 days at 2–8°C; bacteriostatic vs sterile water affects duration
Degradation / stability	Pro residue confers aminopeptidase resistance (longer half-life than α-MSH); main solution pathway = Pro-Val bond hydrolysis; oxidation minimal (no Met/Cys)

Primary-literature citation leads (PeptideBiologix; confirm before citing): Hiltz & Lipton 1989 (FASEB J 3:2282–2284 — already verified in-article); Brzoska et al. 2003 (PMID 12892743); Dalmasso et al. 2008 (PMID 18061177 — already verified in-article); Kannengiesser et al. 2008 colitis model (PMID 17327101). Note: some PMIDs in the raw capture are mis-attributed (e.g., the “Ceriani et al. 1994” and “Dalmasso 2008” links resolve to different records) — verify each before citing.

Sources

• the sourced capture file behind this article (mechanism, dosing, condition map, primary-literature pins).
• inside-the-cell / PepT1-door mechanism, receptor-independence, the “do-not-do” rule, KPV→BPC-157 sequencing, bronchial + metabolic-syndrome angles.
• expanded condition map (MCAS, autoimmune, skin, CNS), tight-junction + TLR4 mechanisms, “modulates not suppresses” framing.
• route-by-use-case, dose/cycle table, gut trio + KLOW 5:1:1:1 ratio.
• evidence layer; see also wiki/immune-cluster-ll37-kpv-vip.md for KPV in its three-peptide cluster context.
• one practitioner’ KPV masterclass (added the 1989 Hiltz/Lipton discovery, the importin α-3 mechanism specificity, the 3-tier dose framework, hs-CRP tracking, PCAC July 2026 update, supplement stack support, die-off caution, GLP-1 + antibiotic interaction notes, next-gen compounds — KDPT, CKPV2, nanoparticle delivery).
• one practitioner’s 60-min “Inflammation Is Killing You, KPV is the Answer.” Source for the cardiovascular / endothelial / neuroinflammation extension section above. Anchored on the verified Ridker 2002 NEJM analysis (PMID 12432042) showing CRP is a stronger first-cardiovascular-event predictor than LDL across 27,939 women followed 8 years. Plus the Catania 2019 metabolic-syndrome marker table, the BDNF / microglial inhibition framing, the one practitioner-published 200 mcg SubQ daily protocol + TB-500 companion for established cardiac disease. Specific KPV percentage improvements from named studies (Peschke 2017 endothelial tight junctions, ICAM/VCAM 2014 Atherosclerosis, Catania 2017 foam cells, 2019 plaque stability, Brain Behavior and Immunity 2017 microglia, Journal of Neuroinflammation 2016 BDNF, Alzheimer’s & Dementia 2018 cognitive decline) all on the queue — extracted with mechanism plausibility intact, percent values flagged pre-publish.
• one practitioner’s ~57-min “KPV and TB500N vs Cholesterol, AFib and Heart Disease.” Adds: (1) SPM production data — Ganning 2018 (Immunology): lipoxin A4 + resolvin D1 +35–42%; (2) T-reg / IL-10 restoration — Catania 2012 (Current Medicinal Chemistry); (3) mast cell stabilization — Powner 2014 (Journal of Immunology); (4) HDL/APOA1 restoration — Cattaneo 2018 (Journal of Lipid Research, APOA1 +29%); (5) Catania 2016 (Inflammation Research): TNF-α -41%, IL-6 -38%, IL-1β -33% in CV inflammation patients; (6) Catania 2018 (Peptides): HOMA-IR -35%; (7) Peschke 2017 (Vascular Medicine Review, n=120): VE-cadherin +28%, occludin +34%; (8) Catania 2019 (Atherosclerosis, n=156 ASCVD): CRP -52%, FMD +28%, CAC -11%, events -35%, 6-month durability; (9) Serhan 2017 (Nature Reviews Immunology) SPM meta-analysis; (10) Ferrucci & Fabbri (Gerontology) centenarian immune profile; (11) updated cardiac restoration protocol with combination 12-week outcome data; (12) statin critique data (all). All on the VERIFY queue — extracted with mechanism plausibility intact.
• Verified primary literature:
  • Hiltz ME, Lipton JM. “Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH.” FASEB J. 1989;3:2282–2284. The discovery paper. ✅ verified 2026-06-16.
  • Dalmasso G, et al. “PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.” Gastroenterology. 2008;134(1):166–178. PMID 18061177, PMC2431115. ✅ verified.
  • “Critical Role of PepT1 in Promoting Colitis-Associated Cancer and Therapeutic Benefits of the Anti-inflammatory PepT1-Mediated Tripeptide KPV in a Murine Model.” Cell Mol Gastroenterol Hepatol. 2016. ✅ verified.
  • Kannengiesser K, et al. “Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists.” Br J Pharmacol. 2012. PMID 22837805, PMC3403564. ✅ verified 2026-06-16 — this paper pins both the importin α-3 / p65 mechanism AND the bronchial-epithelial NF-κB use case (resolving the prior wiki).
  • Getting SJ et al. — MC1R-null receptor-independence.
  • Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. “Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.” NEJM 2002;347(20):1557-1565. PMID 12432042. DOI 10.1056/NEJMoa021993. ✅ verified 2026-06-21 — N=27,939 women, 8-year follow-up, CRP relative risks 1.4/1.6/2.0/2.3 across quintiles vs LDL 0.9/1.1/1.3/1.5. The anchor citation for the cardiovascular section’s inflammation-as-driver framing.
• Verified regulatory: FDA Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026 — KPV/BPC-157/TB-500/MOTS-c on July 23; DSIP/Semax/Epithalon on July 24. Indications under review for KPV: wound healing + inflammatory conditions. ✅ verified 2026-06-16. PCAC vote outcome: 8-6 in favor of recommendation for 503A listing. ✅ confirmed 2026-07-24.
• Lee et al. 2026 (Cytotechnology Vol. 78(3):98, PMID 42064835, DOI 10.1007/s10616-026-00967-z, PMC13125694 available 2027-06-01). Source for the hepatoprotective / NAFLD ROS/PPARγ mechanism finding. In-vitro (HepG2) only; full text Springer-paywalled; digest built from published abstract.

Related: KLOW · BPC-157 · TB-500 · GHK-Cu · GLOW · gut-health-trio-bpc157-kpv-larazotide (framework guide — KPV as the downstream inflammation-modulation layer of the three-mechanism gut-barrier stack) · the LL-37/KPV/VIP immune peptides.